[Federal Register Volume 72, Number 121 (Monday, June 25, 2007)]
[Notices]
[Page 34690]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-12170]



[[Page 34690]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) and the Assistant Secretary for Health have taken final action in 
the following case:
    Diana Layman, University of Oklahoma Health Sciences Center: Based 
on the report of an investigation conducted by the University of 
Oklahoma Health Sciences Center (OUHSC) and additional analysis 
conducted by the Office of Research Integrity during its oversight 
review, the U.S. Public Health Service (PHS) found that Ms. Diana 
Layman, Tribal Efforts Against Lead (TEAL) phlebotomist, OUHSC, engaged 
in scientific misconduct in research supported by National Institute of 
Environmental Health Sciences (NIEHS), National Institutes of Health 
(NIH), grant R01 ES008755.
    Specifically, Ms. Layman falsified research in the TEAL study by 
substituting or conspiring with another phlebotomist to substitute her 
blood or blood of another phlebotomist for blood samples of 10-15 child 
participants in the TEAL study. Ms. Layman has entered into a Voluntary 
Exclusion Agreement (Agreement) in which she has voluntarily agreed, 
for a period of three (3) years, beginning on May 30, 2007:
    (1) To exclude herself from any contracting or subcontracting with 
any agency of the United States Government and from eligibility or 
involvement in nonprocurement programs of the United States Government 
as defined in HHS' implementation of OMB Guidelines to Agencies on 
Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and
    (2) To exclude herself from serving in any advisory capacity to 
PHS, including but not limited to service on any PHS advisory 
committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John E. Dahlberg,
Acting Director, Office of Research Integrity.
 [FR Doc. E7-12170 Filed 6-22-07; 8:45 am]
BILLING CODE 4150-31-P